Characterization of Gp41 Polymorphisms in the Fusion Peptide Domain and T-20 (Enfuvirtide) Resistance-Associated Regions in Korean HIV-1 Isolates

Dai-Ho Jang,1,2* Cheol-Hee Yoon,1* Byeong-Sun Choi,1 Yoon-Seok Chung,1 Hye-Young Kim,2 Sung-Gil Chi,3 and Sung Soon Kim2

1Division of AIDS, Korea National Institute of Health, Cheongwon; 2School of Life Sciences and Biotechnology, Korea University, Seoul, Korea
*Corresponding authors.

Received: 19 August 2013
Accepted: 16 December 2013

Keywords: Fusion Inhibitor; Fusion Peptide; Gp41 Polymorphism; HIV-1 Envelope Glycoprotein; T-20 Resistance Mutation

HIV-1 gp41 is an envelope protein that plays an essential role in virus entry. The mutation of gp41 affects HIV-1 entry and susceptibility to the fusion inhibitor T-20. Therefore, we analyzed the natural polymorphism of gp41 of 163 HIV-1 isolates from T-20-naïve Koreans infected with HIV-1. This study of gp41 polymorphisms showed that insertions in the fourth threonine (74.8%) and L7M substitutions (85.3%) were more frequent in the fusion peptide motif in Korean HIV-1 isolates compared with those from other countries. Minor T-20 resistance mutations such as L45M (1.2%), N126K (1.2%), and E137K (6.7%) were detected, but the critical T-20 resistance mutations were not detected in the gp41 HR1 and HR2 regions. In addition, the N425 mutation (12.9%) associated with T-20 hypersusceptibility was detected at a high frequency. These results may serve as useful data for studies considering T-20 for use in the development of a more effective anti-retroviral treatment in Korea.

AIDS is a disease caused by HIV infection, which destroys the CD4 T cells responsible for cell-mediated immunity in the human body, thereby undermining the immune system. HIV infections have spread gradually since the first case was reported in the USA in 1981 (1). In Korea, the first patient was identified in 1985, with the number of HIV-infected patients rising to 8544 by 2011 (2). The increasing number of HIV-1-infected patients in Korea is causing novel clinical problems such as increased drug resistance in patients treated with highly active antiretroviral therapy (HAART), thus raising the need to develop more effective therapies for patients for whom antiretroviral treatment is or has been unsuccessful (3).

Recently, the HIV-1 envelope glycoprotein was highlighted as an important alternative target for the development of new antiretroviral drugs and vaccines. The glycoprotein is expressed as a polyprotein, which is subsequently cleaved into two subunits, gp120 and gp41, by the host furin (subtilysin proteinase) (4). Despite the more stable genetic characteristics of gp41 compared with gp120, mutations in gp41 may affect HIV-1 entry, pathogenesis, escape from host immune pressure, and resistance to the fusion inhibitor T-20 (enfuvirtide, Fuzeon®). HIV-1 gp41 protein plays an essential role in virus-cell fusion and has a complex structure with three functionally critical domains. The fusion peptide (FP) at the amino (N) terminal of gp41 normally contains 20 amino acids, which attach directly to membrane of the host cell during the first step of fusion. The 16 residues of FP (AVGIGALFLGFLGAAG) are mainly hydrophobic, and facilitate attachment to the cell's membrane. In particular, the conserved FLGFL motif at positions 8–12 has been reported to be essential for fusogenic activities (5). Recent studies have shown that mutations with a polar residue inserted into this motif, such as V2E and L9R substitutions, reduced its fusogenic activity significantly (6).

Other structures in gp41 that are important for viral fusion are two helical repeats, heptad repeat 1 (HR1) and HR2, which include hydrophobic regions that interact with each other during virus-cell fusion via the formation of a six-helix bundled structure (7). The integrity of both repeats is important for the formation of a functional fusogenic complex. Therefore, the HR1 and HR2 domains of gp41 have been considered as potential targets for anti-HIV-1 therapy.

The HIV fusion inhibitor T-20, a synthetic 36-amino acid pep-
tide, which is a homolog of amino acids 127-162 in the HR2 region, was approved as a new class of antiretroviral drug that targets the HR1 domain of gp41 (7). T-20 can restrict HIV-1 replication in an efficient manner (7), but several T-20 resistance mutations have been reported in HR1 as follows: G36D/S, I37V, V38A/M/E, Q39R, Q40H, N42S/T/D/E, N43D/K/S, I44M, L45M, G36S/L44M, G36S/V38M, V38A/N42D, V38A/N42T, V38E/N42S, N42T/N43S and N42T/N43K (8). Recently, it has also been reported that T-20 resistance is greatly increased by a combined mutation of HR1 with secondary and/or compensatory mutations in the HR2 region (N126K, E137K, S138A) (9). Although T-20 therapy is known to efficiently control viral load in HIV-1 infected patients, mutation associated with T-20 resistance was observed to allow persistent replication under T-20 treatment in a clinical study (10).

In this study, we analyzed the distributions of HIV-1 gp41 polymorphisms and T-20 resistance mutations in order to determine whether T-20 is suitable for treating Korean patients infected with HIV-1. We studied HIV-1 isolates from 163 T-20-naive HIV-1 infected patients who were diagnosed in Korea National Institute of Health (KNIH) in the period 2009-2011. The median CD4+ count was 291 cells/μL, and fifteen patients received effective ART (9.2%). Peripheral blood mononuclear cells (PBMCs) were obtained from these patients. The HIV-1 gp41 genes were amplified by nested DNA PCR. The HIV-1 gp41 polymorphisms were analyzed using bioinformatics software DNASTAR® (DNASTAR Inc, Madison, Wisconsin, USA) (11) and compared with the gp41 regions of then reference strain HXB2.

Previously, we reported that the dominant Korean HIV-1 subtype was Korean B subtype, which was classified into a separate branch compared with isolates obtained from North Americans and Europeans (12). In the present study, the distribution of the HIV-1 subtypes in our 163 HIV-1-infected patients comprised 148 patients with subtype B and 15 with non-B subtypes, which were identified as subtypes G (n = 6), A (n = 1), AE (n = 3), C (n = 1), and E (n = 3).

In our FP analysis, we found that there were no variations in the FLGFL motif, but that there were many specific insertional mutations of polar uncharged (threonine: T) and non-polar hydrophobic amino acids (valine, V; alanine, A; isoluecine, I; and methionine, M) in position 4. Table 1 shows that the dominant mutation was a T-insertion mutation (n = 122, 74.8%), while an L7M substitution near the FLGFL motif was also frequent in HIV-1-infected patients (n = 139, 85.3%). Glycine insertions were observed in the reference J, K, and N subtypes obtained from the database of the Los Alamos National Laboratory (http://www.hiv.lanl.gov/content/index), but insertions of polar and other non-polar residues were detected for the first time in our study. In addition, many of the FPs in Korean HIV-1 isolates had L7M substitutions near the FLGFL motif. These mutated residues generally have hydrophobic side chains, with the exception of the fourth threonine insertion, but further investigations should be performed to determine the mutation-related fusion activities of Korean HIV-1 gp41.

| FP | HXB2 | Amino acid polymorphism in clade B (n = 148)* | Amino acid polymorphism in non-clade B (n = 15) | Amino acid polymorphism in subtype reference (n = 39) |
|----|------|---------------------------------------------|---------------------------------------------|--------------------------------------------------|
| 1  | A    | D (1)                                       |                                             |                                                  |
| 2  | V    | I (3), L (2)                                | A (1), I (6), F (2)                         |                                                  |
| 3  | G    | T (2)                                       | A (6), I (1), M (2), T (118), V (4)*       | T (4), A (2), G (2)                              |
| 4  | I    | F (5), L (59), M (3), V (2)                 | L (5)                                       | L (21), M (7), F (1), V (2)                     |
| 5  | G    |                                             |                                             |                                                  |
| 6  | A    |                                             |                                             |                                                  |
| 7  | L    | M (130), V (9)                              | F (2), M (9), V (4)                         | M (5), V (18), F (2), I (1)                     |
| 8  | F    | L (1)                                       | I (6), L (1)                                |                                                  |
| 9  | L    |                                             |                                             |                                                  |
| 10 | G    |                                             |                                             |                                                  |
| 11 | F    |                                             |                                             |                                                  |
| 12 | L    |                                             |                                             |                                                  |
| 13 | G    |                                             |                                             |                                                  |
| 14 | A    |                                             |                                             |                                                  |
| 15 | A    |                                             |                                             |                                                  |
| 16 | G    |                                             |                                             |                                                  |
| 17 | S    |                                             |                                             |                                                  |
| 18 | T    |                                             |                                             |                                                  |
| 19 | M    |                                             |                                             |                                                  |
| 20 | G    |                                             |                                             |                                                  |

*This table shows the single-letter codes for the amino acids at each position in the HXB2 reference strain. †Number of isolates. ‡Amino acids identified as insertional mutations. FP, Fusion Peptide; HXB2, HIV-1 reference strain.

Several in vitro studies have reported that the loss of T-20 susceptibility is closely related to mutations at positions 36-38 in the GIV motif, which is the T-20-binding domain in the HR1 region (13). Moreover, single- or double-amino acid mutations at positions 36-45 in the HR1 region reduced the susceptibility to T-20 by 5- to 100-fold, while the presence of more than three mutations in the HR1 region reduced the susceptibility by > 400-fold (14). Under selective drug pressure, the low fidelity of HIV-1 reverse transcriptase could lead to the development of T-20 resistance mutations (15). Several mutations (N126K, E137K, and S138A) in the HR2 domain contributed to enhanced viral fusion activity and reduced the susceptibility to T-20 (16). The susceptibility was dramatically reduced by about 1,000-fold, and the structural stability of the HR/HR2 complex was improved when the HR1 resistance mutations were coupled with HR2 resistance mutations (16). In addition, minor mutations associated with reduced susceptibility to T-20 have been reported in several countries as follows: N42S (23%), L44M (2.5%), G36S (0.5%), and S138A (4%) in Spain (17); N43K (1.8%), L44M (2.5%), E137K (10%), and S138A (2.5%) in Brazil (18); N42S (16.4%) and E137K (25%) in Italy (19); and L44M (1.7%), N42S (16%), E137K (25%...
Overall, our results suggest that the genetic variation of gp41 in specific countries may be provided as useful information to consider T-20 for studies considering the use of T-20 in the development of a more effective anti-retroviral treatment in Korea.

**DISCLOSURE**

The authors declare that they have no competing interests.

**REFERENCES**

1. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, Saxen A. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981; 305: 1425-31.

2. Kee MK, Lee JH, Whang J, Kim SS. Ten-year trends in HIV prevalence among visitors to public health centers under the National HIV Surveillance System in Korea, 2000 to 2009. BMC Public Health 2012; 12: 831.

3. Kim JY, Kim EJ, Choi JY, Kwon OK, Kim GI, Choi SY, Kim SS. Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naive patients with HIV/AIDS in Korea. Clin Microbiol Infect 2011; 17: 1155-9.

4. Pessoa LS, Valadão AL, Abreu CM, Calazans AR, Martins AN, Azevedo SS, Couto-Fernandez JC, Azevedo MC, Tanuri A. Genotypic analysis of the gp41 HR1 region from HIV-1 isolates from enfuvirtide-treated and untreated patients. J Acquir Immune Defic Syndr 2011; 57: S197-201.

5. Pritsker M, Rucker J, Hoffman TL, Dombs RW, Shai Y. Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes. Biochemistry 1999; 38: 11359-71.

6. Morozov VA, Morozov AV, Schürmann D, Jessen H, Kücherer C. Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon) in HIV-1 infected therapy-naïve seroconverters and AIDS patients under HAART-T20 therapy. Virus Genes 2007; 35: 167-74.

7. Kilby JM, Eron JJ. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 2003; 348: 2228-38.

8. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer RW, Wensing AM, Richman DD. Update of the drug resistance mutations list in HIV-1: March 2013. Top Antivir Med 2013; 21: 6-14.

9. Xu L, Pozniak A, Wildfire A, Stanfield-Oakley SA, Mosier SM, Raticliffe D, Workman J, Joall A, Myers R, Smit E, et al. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 2005; 49: 1113-9.

10. Bienvenu B, Krivine A, Rollot F, Pietri MP, Lebault V, Meritet JF, Guerin C, Spiridon G, Salmon D, Guillemin L, et al. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice. J Med Virol 2006; 78: 1312-7.

11. Mink M, Mosier SM, Janumpalli S, Davison D, Jin L, Melby T, Sista P, Erickson J, Lambert D, Stanfield-Oakley SA, et al. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol 2005; 79: 12447-54.
12. Kim GJ, Yun MR, Koo MJ, Shin BG, Lee JS, Kim SS. Estimating the origin and evolution characteristics for Korean HIV type 1 subtype B using Bayesian phylogenetic analysis. AIDS Res Hum Retroviruses 2012; 28: 880-4.

13. Lohrengel S, Hermann F, Hagmann I, Oberwinkler H, Scriver L, Hoffmann C, von Laer D, Dittmar MT. Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides. J Virol 2005; 79: 10237-46.

14. Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004; 54: 333-40.

15. Johnson VA, Brun-Verin F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. Update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med 2006; 14: 125-30.

16. Izumi K, Kawai K, Miyamoto F, Shimane K, Shimura K, Sakagami Y, Hattori T, Watanabe K, Oishi S, Fujii N, et al. Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design. Int J Biochem Cell Biol 2013; 45: 908-15.

17. Carmona R, Pérez-Alvarez L, Muñoz M, Casado G, Delgado E, Sierra M, Thomson M, Vega Y, Vázquez de Parga E, Contreras G, et al. Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients. J Clin Virol 2005; 32: 248-53.

18. Teixeira C, de Sá-Filho D, Alkmim W, Janini LM, Díaz RS, Komninakis S. Short communication: high polymorphism rates in the HR1 and HR2 gp41 and presence of primary resistance-related mutations in HIV type 1 circulating in Brazil: possible impact on enfuvirtide efficacy. AIDS Res Hum Retroviruses 2010; 26: 307-11.

19. Hudelson SE, Marlowe N, Huang W, Bruce R, Church JD, Husnik M, Donnell D, Coates T, Jackson JB, Chesney M, et al. Analysis of HIV type 1 gp41 and enfuvirtide susceptibility among men in the United States who were HIV infected prior to availability of HIV entry inhibitors. AIDS Res Hum Retroviruses 2009; 25: 701-5.

20. Aquaro S, D’Arrigo R, Svicher V, Perri GD, Caputo SL, Visco-Comandini U, Santoro M, Bertoli A, Mazzotta F, Bonora S, et al. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 2006; 58: 714-22.